TY  - JOUR
T1  - Clarification of conflict of interest disclosures in: Preventing depression: a global priority
Y1  - 2012/06/06
N1  - 10.1001/jama.2012.5453
JO  - JAMA
SP  - 2259
EP  - 2259
VL  - 307
IS  - 21
N2  - 
Clarification of Conflict of Interest Disclosures:  In a Viewpoint entitled, “Preventing Depression: A Global Priority,” published in the March 14, 2012, issue of JAMA (2012;307[10]:1033-1034), the conflict of interest disclosure for Dr Reynolds should have read as follows: “Dr Reynolds reported receiving pharmaceuticals for research studies from Bristol-Myers Squibb, Forest, Pfizer, and Lilly; receiving grants from the National Institute of Mental Health, National Institute on Aging, National Center on Minority Health and Health Disparities, National Heart, Lung, and Blood Institute, the Commonwealth of Pennsylvania, the John A Hartford Foundation, and the American Foundation for Suicide Prevention; and serving on the American Association for Geriatric Psychiatry editorial review board.” A letter regarding the correction appears in this issue. The article has been corrected online.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.5453
UR  - http://dx.doi.org/10.1001/jama.2012.5453
ER  -